Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Eisenmenger Syndrome: Recent Advances in Pharmacotherapy

Author(s): Sarmad Said, Mateo Porres-Aguilar, Mateo Porres-Munoz and Debabrata Mukherjee

Volume 11, Issue 4, 2013

Page: [289 - 296] Pages: 8

DOI: 10.2174/1871525712666140321095519

Price: $65

Abstract

Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.

Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy